Notice |
How to write your comments onto a webpage
[2]
| 2016.07.06 | 운영자 | 2016.11.20 | 18193 |
Notice |
How to Upload Pictures in webpages
| 2016.07.06 | 운영자 | 2018.10.19 | 32347 |
Notice |
How to use Rich Text Editor
[3]
| 2016.06.28 | 운영자 | 2018.10.19 | 5924 |
Notice |
How to Write a Webpage
| 2016.06.28 | 운영자 | 2020.12.23 | 43840 |
663 |
What An Incredible Story!
[3] | 2019.07.27 | 이한중*65 | 2019.07.27 | 30383 |
662 |
[Medical] ABCD2 for Stroke
[1] | 2013.03.23 | 이한중*65 | 2013.03.23 | 29144 |
661 |
[Medical]Tylenol Use During Pregnancy, Warned
[1] | 2021.09.24 | 이한중*65 | 2021.09.24 | 21304 |
660 |
Norovirus Strikes Hundreds in Cruise Ship Again
[1] | 2016.05.08 | 이한중 | 2016.05.08 | 21146 |
659 |
[Medical] COVID-19: Anticoagulation Even After Discharge
[1] | 2020.05.01 | 이한중*65 | 2020.05.01 | 18534 |
658 |
[Medical] Lp(a), The Last Frontier of CVD Risk, Conquered?
[4] | 2020.01.02 | 이한중*65 | 2020.01.05 | 16655 |
657 |
[Medical] ARBs Protect Against Alzheimer's
| 2012.10.22 | 이한중*65 | 2012.10.22 | 13270 |
656 |
♥ 혈관경련성 협심증(Vasospastic Angina)의 치료
| 2010.04.19 | 이종구*57 | 2010.04.19 | 12426 |
655 |
[Medical] PIP Approach For PAF Management
[3] | 2019.10.15 | 이한중*65 | 2019.10.18 | 12260 |
654 |
Clot-busting Treatment - A new hope in COVID-19?
[6] | 2020.04.12 | 운영자 | 2020.04.14 | 11265 |
653 |
♥ 동맥 맥파속도(Pulse Wave Velocity)와 경직성(Stiffness)의 중요성
| 2010.01.18 | 이종구*57 | 2010.01.18 | 10868 |
652 |
♥ 악성, 양성 콜레스테롤, 중성지방, 대사증후군-1
| 2009.10.12 | 이종구*57 | 2009.10.12 | 10663 |
651 |
[Medical]Finger Prick INR Testing Device Accuracy Concerns
[1] | 2016.03.17 | 이한중*65 | 2016.03.17 | 10469 |
650 |
♥ 만성이완기 심부전증(Diastolic Heart Failure) 진단-치료
| 2010.07.19 | 이종구*57 | 2010.07.19 | 10406 |
649 |
[Medical] Atrial Fibrillation / Brian F. Mandell, MD, PhD
[4] | 2012.08.01 | 이한중*65 | 2012.08.01 | 10356 |
648 |
♥ 스타틴의 약물과 약물 상호작용
[1] | 2010.05.10 | 이종구*57 | 2010.05.10 | 10225 |
647 |
♥ 악성, 양성 콜레스테롤, 중성지방, 대사증후군-2
[1] | 2009.10.19 | 이종구*57 | 2009.10.19 | 10118 |
646 |
♥ 난치성 고혈압: 저염食과 Aldosterone 억제제가 효과
| 2010.08.18 | 이종구*57 | 2010.08.18 | 10066 |
645 |
The lab-leak theory
[7] | 2021.05.27 | 이병붕*63 | 2021.05.29 | 9998 |
644 |
♥ 악성, 양성콜레스테롤, 중성지방, 대사증후군-3
[1] | 2009.10.26 | 이종구*57 | 2009.10.26 | 9890 |
Baloxavir Marboxil for Prophylaxis against Influenza in Household Contacts
List of authors.
Abstract
BACKGROUND
Baloxavir marboxil (baloxavir) is a polymerase acidic protein (PA) endonuclease inhibitor with clinical efficacy in the treatment of uncomplicated influenza, including in outpatients at increased risk for complications. The postexposure prophylactic efficacy of baloxavir in the household setting is unclear.
METHODS
We conducted a multicenter, double-blind, randomized, placebo-controlled trial to evaluate the postexposure prophylactic efficacy of baloxavir in household contacts of index patients with confirmed influenza during the 2018–2019 season in Japan. The participants were assigned in a 1:1 ratio to receive either a single dose of baloxavir or placebo. The primary end point was clinical influenza, as confirmed by reverse-transcriptase–polymerase-chain-reaction testing, over a period of 10 days. The occurrence of baloxavir-selected PA substitutions associated with reduced susceptibility was assessed.
RESULTS
A total of 752 household contacts of 545 index patients were randomly assigned to receive baloxavir or placebo. Among the index patients, 95.6% had influenza A virus infection, 73.6% were younger than 12 years of age, and 52.7% received baloxavir. Among the participants who could be evaluated (374 in the baloxavir group and 375 in the placebo group), the percentage in whom clinical influenza developed was significantly lower in the baloxavir group than in the placebo group (1.9% vs. 13.6%) (adjusted risk ratio, 0.14; 95% confidence interval [CI], 0.06 to 0.30; P<0.001). Baloxavir was effective in high-risk, pediatric, and unvaccinated subgroups of participants. The risk of influenza infection, regardless of symptoms, was lower with baloxavir than with placebo (adjusted risk ratio, 0.43; 95% CI, 0.32 to 0.58). The incidence of adverse events was similar in the two groups (22.2% in the baloxavir group and 20.5% in the placebo group). In the baloxavir group, the viral PA substitutions I38T/M or E23K were detected in 10 (2.7%) and 5 (1.3%) participants, respectively. No transmission of these variants from baloxavir-treated index patients to participants in the placebo group was detected; however, several instances of transmission to participants in the baloxavir group could not be ruled out.
CONCLUSIONS
Single-dose baloxavir showed significant postexposure prophylactic efficacy in preventing influenza in household contacts of patients with influenza. (Funded by Shionogi; Japan Primary Registries Network number, JapicCTI-184180.)(NEJM July 8, 2020)